1Schenk D, Barbour R, Dunn W, et al. Immunization with amyloidbeta attenuates Alzheimer-disease-like pathology in the PDAPP mouse[J]. Nature, 1999, 400(6740): 173 - 177.
2Arendash GW, Gordon MN, Diamond DM, et al. Behavioral assessment of Alzheimer' s transgenic mice following long-term Abeta vaccination: task specificity and correlations between Abeta deposition andspatial memory [ J]. DNA Cell Biol, 2001, (11): 737 -744.
3Schenk D. Amyloid-beta immunotherapy for Alzheimer's disease: the endof the beginning [J]. Nat Rev Neurosci, 2002, 3(10): 824 -828.
4Ott G. The adjuvant MF59: the 1998 perspective, clinical, persormanceand mechanism of action [J]. Res immunol, 1998, 149:25 -27.
6Ott G, Barchfeld GL, Van Nest G, et al. Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59 [J]. Vaccine, 1995, 13(16): 1557-1562.
7Plduslo JF, Cunan GL. Amyloid beta peptide as a vaccine for Alzheimer's disease involves receptor-mediated transport at the blood-brainbarrier [J]. Neuroreport, 2001, 12(15): 3197-3200.
8Dohart JC, Bales Kr, Gannon KS, et al. Immunizarion reverses memory deficits without reducing brain Aβ burden in Alzheimer' s diseasemodel [J]. Nat Neurosci, 2002, 5 (5): 452 -457.
9Jams AR, Nicoll, David W, et al. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report[J]. NatMed, 2003, 10: 1-5.
10Hock C, Konietzko U, Papassotiropoulos A, et al.Generation of antibodies specific for β-amyloid by vaccination of patients with Alzheimer disease[J] . Nature Medicine, 2002, 8(11): 1270-5.
